Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep

Edesa Biotech, Inc.

Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.
Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.
Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.
EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.
Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.